A Study of E6742 in Participants With Systemic Lupus Erythematosus

Exclusion criteria

• . Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] or human chorionic gonadotropin \[hCG\] test). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
• . Females of childbearing potential who:
• . Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:
• . Do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation.
• . Participants on an oral contraceptive must use an additional barrier method throughout the study and for 28 days after study drug discontinuation.
• . Males who have not had a successful vasectomy (confirmed azoospermia) if their female partners meet the exclusion criteria above (ie, the female partners are of childbearing potential and are not willing to use a highly effective contraceptive method throughout the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation). No sperm donation is allowed during the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation.
• . Drug-induced lupus erythematosus
• . Active or unstable neuropsychiatric lupus (including but not limited to any condition defined by BILAG category A in neuropsychiatric organ system)